Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, and Chembio Diagnostics, Inc. (“Chembio”) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced that the companies have entered into a definitive merger agreement under which Biosynex, through a subsidiary, will acquire Chembio for $0.45 per share, representing a premium of 27% compared to the closing price of Chembio stock on January 30, 2023, in an all-cash transaction valued at $17.2 million. The acquisition combines two leading rapid diagnostic test companies. Each company specializes in the development, manufacturing and marketing of point-of-care diagnostic tests for the professional and at home markets.
Read the full article: Biosynex and Chembio Diagnostics Announce Definitive Acquisition Agreement //
Source: https://www.globenewswire.com/news-release/2023/01/31/2599006/21088/en/Biosynex-and-Chembio-Diagnostics-Announce-Definitive-Acquisition-Agreement.html